Benitec's Hepatitis C Drug Resurrected by Startup Company and Industry Veterans
October 12, 2006
Benitec's Hepatitis C Drug Resurrected by Startup Company and Industry Veterans
Tacere Therapeutics, whose name is Italian for “to be silent,” was founded in July by two Benitec alums including former CEO Sara Cunningham Hall and ex-CFO Mike Catelani. The company plans to pursue both RNAi and small molecule therapeutics for hepatitis C.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 23, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 23, 2013 / Gene Silencing News - MiRagen Hits First Milestone in Servier microRNA Drug Partnership
May 23, 2013 / Gene Silencing News - Cenix to Provide Research Services to Debiopharm
May 23, 2013 / Gene Silencing News